Stock EPI ESSA PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

ESSA Pharma Inc. Share Price Toronto S.E.

Equities

EPI

CA29668H7085

Biotechnology & Medical Research

Financials

Sales 2024 * - Sales 2025 * - Capitalization 376M 276M 21.7B
Net income 2024 * -46M -33.76M -2.66B Net income 2025 * -72M -52.84M -4.16B EV / Sales 2024 * -
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
-8.2 x
P/E ratio 2025 *
-6.11 x
Employees 50
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.73%
More Fundamentals * Assessed data

Chart ESSA Pharma Inc.

Dynamic Chart

Latest news about ESSA Pharma Inc.

Top Premarket Decliners MT
Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call
Norway's wealth fund pushes for more women on emerging market company boards RE
ESSA Pharma Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
ESSA Pharma Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023 CI
Essa Pharma Insider Bought Shares Worth $133,274, According to a Recent SEC Filing MT
Essa Pharma Insider Bought Shares Worth $419,661, According to a Recent SEC Filing MT
ESSA Pharma Inc. Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat CI
ESSA Pharma Files $200 Million Mixed Shelf MT
ESSA Pharma Inc. Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer CI
ESSA Pharma Inc.(NasdaqCM:EPIX) dropped from S&P Global BMI Index CI
ESSA Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Essa Pharma Inc. Appoints Lauren Merendino to Its Board of Directors CI
ESSA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
ESSA Pharma Signs Clinical Trial Support Deal With Janssen to Evaluate EPI-7386 Combinations to Treat Prostate Cancer MT
More news

Latest transcript on ESSA Pharma Inc.

Logo ESSA Pharma Inc.
ESSA Pharma Inc. - Shareholder/Analyst Call
More transcripts

Analyst Recommendations on ESSA Pharma Inc.

Oppenheimer Adjusts ESSA Pharma's Price Target to $17 From $23, Maintains Outperform Rating MT
Oppenheimer Adjusts ESSA Pharma Price Target to $23 From $22, Maintains Outperform Rating MT
Piper Sandler Adjusts ESSA Pharma's Price Target to $20 From $50, Reiterates Overweight Rating MT
ESSA PHARMA : Oppenheimer Adjusts ESSA Pharma PT to $22 From $36 on Delayed EPI-7386 Clinical Update, Maintains Outperform Rating MT
ESSA PHARMA : Piper Sandler Starts ESSA Pharma at Overweight With $50 Price Target MT
More recommendations

Press releases ESSA Pharma Inc.

ESSA Pharma: Fiscal Q2 Earnings Snapshot AQ
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 PR
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference PR
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS PR
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS AQ
More press releases

News in other languages on ESSA Pharma Inc.

BB Biotech bestätigt Verlust für 2022 - Erwartet mehr Aktivität 2023
More news

Managers and Directors - ESSA Pharma Inc.

Managers TitleAgeSince
David Parkinson CEO
 Chief Executive Officer 73 23/06/15
David Wood DFI
 Director of Finance/CFO 66 30/09/13
Peter Virsik COO
 Chief Operating Officer - 31/07/16
Members of the board TitleAgeSince
Franklin Berger BRD
 Director/Board Member 74 04/03/15
Sanford Zweifach BRD
 Director/Board Member 68 30/07/19
Richard Glickman CHM
 Chairman 65 30/09/10
More insiders

Company Profile

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Sector
Biotechnology & Medical Research
Calendar
12/08/2024 - Q3 2024 Earnings Release (Projected)
More about the company

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+41.79% 50.93B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.56% 42.12B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.05B
CELLTRION, INC. Stock Celltrion, Inc.
-7.20% 29.18B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.59% 26.02B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.51% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+6.92% 13.21B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.91% 12.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.60% 12.16B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EPIX Stock
  4. EPI Stock